• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细菌纤维素固定的 I-αPD-L1 增强癌症的放射免疫治疗。

I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer.

机构信息

State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, China.

State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, China.

出版信息

J Control Release. 2022 Jun;346:240-249. doi: 10.1016/j.jconrel.2022.04.029. Epub 2022 Apr 26.

DOI:10.1016/j.jconrel.2022.04.029
PMID:35469982
Abstract

Radioisotope therapy (RIT) of cancer is restrained by the nonspecific distribution of radioisotope and ineptitude for metastatic tumors. Meanwhile, the clinical application of immune checkpoint blockade (ICB) confronts problems such as low responsive rate, multiple administration requirements and immune-related adverse events (irAE). To address these challenges, we prepared an injectable suspension by immobilizing I-labeled anti-programmed cell death-ligand 1 antibody (αPD-L1) in bacterial cellulose for precise and durable radio-immunotherapy of cancer. The crisscross network structure of bacterial cellulose nanofibers would contribute to the long-term retention of I-labeled αPD-L1 within tumors, which could reduce the side effect stemmed from the nonspecific I distribution in normal tissues. The potent long-term RIT of I, combined with ICB by αPD-L1, could effectively restrain the growth of primary tumor in mice. In addition to the direct killing effect, I-αPD-L1 immobilized by bacterial cellulose could enhance the immunogenic cell death (ICD) of cancer cells, activating the maturation of multiple immune cells to induce a systemic anti-tumor immune effect. Our therapeutic strategy could suppress spontaneous cancer metastasis and prolong the survival time of tumor-bearing mice. This study proposed a new approach for combined radio-immunotherapy and a novel solution for tumor metastasis in advanced-stage cancers.

摘要

癌症的放射性同位素治疗(RIT)受到放射性同位素的非特异性分布和转移性肿瘤治疗能力的限制。同时,免疫检查点阻断(ICB)的临床应用面临着响应率低、多次给药要求和免疫相关不良事件(irAE)等问题。为了解决这些挑战,我们通过将放射性碘标记的抗程序性细胞死亡配体 1 抗体(αPD-L1)固定在细菌纤维素中来制备可注射悬浮液,以实现癌症的精确和持久的放射性免疫治疗。细菌纤维素纳米纤维的交错网络结构有助于放射性碘标记的 αPD-L1 在肿瘤内的长期保留,从而减少由于正常组织中放射性碘的非特异性分布而引起的副作用。强大的长期放射性碘治疗,结合αPD-L1 的 ICB,可有效抑制小鼠原发性肿瘤的生长。除了直接杀伤作用外,细菌纤维素固定的 I-αPD-L1 还可以增强癌细胞的免疫原性细胞死亡(ICD),激活多种免疫细胞的成熟,诱导全身性抗肿瘤免疫效应。我们的治疗策略可以抑制自发性癌症转移并延长荷瘤小鼠的生存时间。本研究提出了一种联合放射性免疫治疗的新方法,并为晚期癌症的肿瘤转移提供了一种新的解决方案。

相似文献

1
I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer.细菌纤维素固定的 I-αPD-L1 增强癌症的放射免疫治疗。
J Control Release. 2022 Jun;346:240-249. doi: 10.1016/j.jconrel.2022.04.029. Epub 2022 Apr 26.
2
PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a Lu-labeled αPD-L1 antibody.正电子发射断层扫描(PET)成像有助于筛选与 Lu 标记的 αPD-L1 抗体协同放射免疫治疗的抗体。
Theranostics. 2021 Jan 1;11(1):304-315. doi: 10.7150/thno.45540. eCollection 2021.
3
PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.PD-L1 靶向放射性核素治疗联合 αPD-L1 抗体免疫治疗协同增强抗肿瘤作用。
Mol Pharm. 2022 Oct 3;19(10):3612-3622. doi: 10.1021/acs.molpharmaceut.2c00281. Epub 2022 Jun 2.
4
CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.靶向 CD122 的白细胞介素 2 和 αPD-L1 通过不同的机制治疗膀胱癌和黑色素瘤,包括 CD122 驱动的自然杀伤细胞成熟。
Oncoimmunology. 2021 Nov 22;10(1):2006529. doi: 10.1080/2162402X.2021.2006529. eCollection 2021.
5
Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.通过克服小鼠肝脏免疫耐受增强程序性死亡配体 1 抗体治疗转移性肝癌的疗效。
Hepatology. 2022 Sep;76(3):630-645. doi: 10.1002/hep.32266. Epub 2022 Jan 23.
6
Integrin αβ-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy.整合素 αβ 靶向放射性核素治疗联合免疫检查点阻断免疫治疗协同增强抗肿瘤疗效。
Theranostics. 2019 Oct 16;9(25):7948-7960. doi: 10.7150/thno.39203. eCollection 2019.
7
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.肿瘤靶向白细胞介素-12 与恩替诺特联合使用可克服 MHC-I 和 APM 缺陷的 PD-1/PD-L1 阻断耐药肿瘤。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004561.
8
Pleiotropic Immunomodulatory Functions of Radioactive Inactivated Bacterial Vectors for Enhanced Cancer Radio-immunotherapy.放射性灭活细菌载体在增强癌症放射免疫治疗中的多效免疫调节功能
ACS Nano. 2022 Jul 26;16(7):11325-11337. doi: 10.1021/acsnano.2c04982. Epub 2022 Jul 12.
9
Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.肌肉浸润性和转移性膀胱癌的围手术期免疫检查点阻断
J Cancer Immunol (Wilmington). 2024;6(1):29-39. doi: 10.33696/cancerimmunol.6.081.
10
Synergism of Cu-Labeled RGD with Anti-PD-L1 Immunotherapy for the Long-Acting Antitumor Effect.铜标记的 RGD 与抗 PD-L1 免疫治疗的协同作用实现长效抗肿瘤效果。
Bioconjug Chem. 2022 Nov 16;33(11):2170-2179. doi: 10.1021/acs.bioconjchem.2c00408. Epub 2022 Oct 18.

引用本文的文献

1
Radionuclide-labeled nanomaterials for tumor therapy: Recent progress and perspectives.用于肿瘤治疗的放射性核素标记纳米材料:最新进展与展望
Mater Today Bio. 2025 Aug 5;34:102156. doi: 10.1016/j.mtbio.2025.102156. eCollection 2025 Oct.
2
Photo-Thermally Controllable Tumor Metabolic Modulation to Assist T Cell Activation for Boosting Immunotherapy.光热可控的肿瘤代谢调节辅助 T 细胞激活以增强免疫治疗。
Int J Nanomedicine. 2024 Nov 3;19:11181-11194. doi: 10.2147/IJN.S483815. eCollection 2024.
3
Protein Immobilization on Bacterial Cellulose for Biomedical Application.
用于生物医学应用的细菌纤维素上的蛋白质固定化。
Polymers (Basel). 2024 Aug 30;16(17):2468. doi: 10.3390/polym16172468.
4
Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy.放疗联合纳米生物材料用于癌症放免治疗。
J Nanobiotechnology. 2023 Oct 30;21(1):395. doi: 10.1186/s12951-023-02152-2.
5
In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody.放射性核素标记 PD-L1 纳米抗体治疗非小细胞肺癌的体内外研究。
J Cancer Res Clin Oncol. 2023 Sep;149(11):8429-8442. doi: 10.1007/s00432-023-04793-0. Epub 2023 Apr 21.
6
Smart Polymeric Nanoparticles in Cancer Immunotherapy.癌症免疫治疗中的智能聚合物纳米颗粒
Pharmaceutics. 2023 Feb 26;15(3):775. doi: 10.3390/pharmaceutics15030775.
7
Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors.铁死亡与肿瘤免疫治疗:一种有前景的肿瘤联合治疗方法。
Front Oncol. 2023 Feb 8;13:1119369. doi: 10.3389/fonc.2023.1119369. eCollection 2023.
8
Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer.肠道微生物群:结直肠癌放射免疫治疗的新靶点和潜在靶点。
Front Immunol. 2023 Jan 31;14:1128774. doi: 10.3389/fimmu.2023.1128774. eCollection 2023.